Evaluation of symmetric dimethylarginine and creatinine in dogs with primary hypoadrenocorticism receiving long-term mineralocorticoid replacement therapy.
Journal
The Veterinary record
ISSN: 2042-7670
Titre abrégé: Vet Rec
Pays: England
ID NLM: 0031164
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
19
12
2020
received:
05
09
2020
accepted:
15
02
2021
pubmed:
20
4
2021
medline:
11
1
2022
entrez:
19
4
2021
Statut:
ppublish
Résumé
To investigate kidney function by determining serum symmetric dimethylarginine (sSDMA) and serum creatinine (sCr) concentrations in dogs with primary hypoadrenocorticism (PH) receiving long-term mineralocorticoid replacement therapy. Dogs with PH receiving a minimum of 12 months of either desoxycorticosterone pivalate or fludrocortisone acetate were included in the study provided that banked frozen serum samples were available for sSDMA analysis. sCr concentrations were retrieved from the medical records. In dogs still alive and presented for regular re-evaluations and in newly diagnosed patients, blood was prospectively collected for sSDMA and sCr determination. Thirty-two dogs met the inclusion criteria. The treatment time ranged from 12 to 146 months after initial diagnosis (median, 55.5 months). The majority of dogs had normal sSDMA and sCr concentrations throughout the hormone replacement treatment. Both sSDMA and sCr concentrations were persistently elevated in three of 32 dogs. Further workup confirmed chronic kidney disease (CKD) in all three dogs. Based on these data, the prevalence of CKD could be higher in dogs with PH receiving long-term mineralocorticoid replacement treatment than in the general dog population. However, additional studies with a larger number of dogs are needed to confirm it.
Substances chimiques
Mineralocorticoids
0
symmetric dimethylarginine
49787G1ULV
Arginine
94ZLA3W45F
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e242Informations de copyright
© 2021 British Veterinary Association.
Références
Smith SJ, Marcandu ND, Banks RA. Evidence that patients with Addison's disease are undertreated with fludrocortisone. Lancet. 1984;1:11-4.
Oelkers W, Diederich S, Bähr V. Diagnosis and therapy surveillance in Addison´s disease: Rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosteron. J Clin Endocrinol Metab. 1992;75:259-64.
Baumstark ME, Nussberger J, Boretti FS, Baumstark MW, Riond B, Reusch CE, et al. Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterine versus fludrocortison. J Vet Intern Med. 2014;28:1471-8.
Shibata S, Fujita T. Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome. Mol Cell Endocrinol. 2012;350:273-80.
Blasi ER, Rocha R, Rudolph AE, Blomme EAG, Polly ML, Mcmahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Inter. 2003;63:1791-800.
Schmitz, Brand SM, Brand E. Aldosterone signaling and soluble adenylyl cyclase - a nexus for the kidney and vascular endothelium. Biochim Biophys Acta Mol Basis Dis. 2014;1842:2601-9.
Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;6:261-73.
Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261-73.
Waters CB, Adams LG, Scott-Moncrieff JC, Denicola DB, Snyder PW, White MR, et al. Effects of glucocorticoid therapy on urine protein-to-creatinine ratios and renal morphology in dogs. J Vet Intern Med. 1997;11:172-7.
Brown SA, Finco DR, Crowell WA, Choat DC, Navar LG. Single-nephron adaptations to partial renal ablation in the dog. Am J Physiol. 1990;258:495-503.
Nabity MB, Lees GE, Boggess MM, Yerramilli M, Obare E, Yerramilli M, et al. Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for the detection of chronic kidney disease in dogs. J Vet Intern Med. 2015;29:1036-44.
Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum concentrations of symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney disease. J Vet Intern Med. 2016;30:794-802.
Reusch CE, Fracassi F, Sieber-Ruckstuhl NS, Burkhardt WA, Hofer-Inteeworn N, Schuppisser C, et al. Altered serum thyrotropin concentrations in dogs with primary hypoadrenocorticism before and during treatment. J Vet Intern Med. 2017;31:1643-8.
Sieber-Ruckstuhl NS, Reusch CE, Hofer-Inteeworn N, Kuemmerle-Fraune C, Müller C, Hofmann-Lehmann R, et al. Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism. J Vet Intern Med. 2019;33:1266-71.
Rodríguez Piñeiro MI, Benchekroun G, De Fornel-Thibaud P, Maurey-Guenec C, Garnier F, Rosenberg D. Accuracy of an adrenocorticotropic hormone (ACTH) immunoluminometric assay for differentiating ACTH-dependent from ACTH-independent hyperadrenocorticism in dogs. J Vet Intern Med. 2009;23:850-5.
Scott-Moncrieff JC, Koshko MA, Brown JA, Hill K, Refsal KR. Validation of a chemiluminescent enzyme immunometric assay for plasma adrenocorticotropic hormone in the dog. Vet Clin Pathol. 2003;32:180-7.
Polzin D. Chronic kideney disease. In: Ettinger SJ, Feldman EC, Côté E, editors. Textbook of veterinary internal medicine. 8th ed. St. Louis: Elsevier; 2017. p. 1938.
O'neill DG, Elliott J, Church DB, Mcgreevy PD, Thomson PC, Brodbelt DC. Chronic kidney disease in dogs in UK veterinary practices: prevalence, risk factors, and survival. J Vet Intern Med. 2013;27:814-21.
Pelander L, Ljungvall I, Egenvall A, Syme H, Elliott J, Häggström J. Incidence of and mortality from kidney disease in over 600,000 insured Swedish dogs. Vet Rec. 2015;176:656-63.
Kopke MA, Burchell RK, Ruaux CG, Burton SE, Lopez-Villalobos N, Gal A. Variability of symmetric dimethylarginine in apparently healthy dogs. J Vet Intern Med. 2018;32:736-42.
Esposito D, Pasquali D, Johannsson G. Primary adrenal insufficiency: managing mineralocorticoid replacement therapy. J Clin Endocrinol Metab. 2018;103:376-87.
Kaplan AJ, Peterson ME. Effects of desoxycorticosterone pivalate administration on blood pressure in dogs with primary hypoadrenocorticism. J Am Vet Med Assoc. 1995;206:327-31.
Chow E, Campbell WR, Turnier JC, Lynn RC, Pavkov KL. Toxicity of desoxycorticosterone pivalate given at high dosages to clinically normal beagles for six months. Am J Vet Res. 1993;54:1954-61.
Bates JA, Shott S, Schall WD. Lower initial dose desoxycorticosterone pivalate for treatment of canine primary hypoadrenocorticism. Aust Vet J. 2013;91:77-82.
Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, et al. Review: consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014;275:104-15.
Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AFH, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004;151:397-406.
Schellenberg S, Mettler M, Gentilini F, Portmann R, Glaus TM, Reusch CE. The effects of hydrocortison on systemic arterial blood pressure and urinary protein excretion in dogs. J Vet Intern Med. 2008;22:273-81.
Masters AK, Berger DJ, Ware WA, Langenfeld NR, Coetzee JF, Mochel JPM, et al. Effects of short-term anti-inflammatory glucocorticoid treatment on clinicopathologic, echocardiographic, and hemodynamic variables in systematically healthy dogs. Am J Vet Res. 2018;79:411-23.
Toblli JE, Bevione P, Di Gennaro F, Madalena L, Cao G, Angerosa M. Understanding the mechanism of proteinuria: therapeutic implications. Int J Nephrol. 2012;2012:1-13.
Jacob F, Polzin DJ, Osborne CA, Neaton JD, Kirk CA, Allen TA, et al. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. J Am Vet Assoc. 2005;226:393-400.
Rudinsky AJ, Harjes LM, Byron J, Chew DJ, Toribio RE, Langston C, et al. Factors associated with survival in dogs with chronic kidney disease. J Vet Intern Med. 2018;32:1977-82.
Smets P, Meyer E, Maddens B, Daminet S. Cushing's syndrom, glucocorticoids and the kidney. Gen Comp Endocrinol. 2010;169:1-10.
Reusch CE. Glucocorticoid therapy. In: Feldman EC, Nelson RW, Reusch CE. editors. Canine and feline endocrinology. 4th ed. St. Louis: Elsevier; 2015. p. 555.